Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study

• Published in: Gut microbes Vol. 14; no. 1; p. 2003176
• Main Authors: Wang, Shujie, Ren, Huahui, Zhong, Huanzi, Zhao, Xinjie, Li, Changkun, Ma, Jing, Gu, Xuejiang, Xue, Yaoming, Huang, Shan, Yang, Jialin, Chen, Li, Chen, Gang, Qu, Shen, Liang, Jun, Qin, Li, Huang, Qin, Peng, Yongde, Li, Qi, Wang, Xiaolin, Zou, Yuanqiang, Shi, Zhun, Li, Xuelin, Li, Tingting, Yang, Huanming, Lai, Shenghan, Xu, Guowang, Li, Junhua, Zhang, Yifei, Gu, Yanyun, Wang, Weiqing
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2022; Taylor & Francis Group
• Subjects: Adult; Animals; berberine; Berberine - administration & dosage; Cholesterol - blood; Cholesterol, LDL - blood; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - microbiology; Double-Blind Method; Drug Therapy, Combination; dyslipidemia; Feces - microbiology; Female; Gastrointestinal Microbiome - drug effects; gut microbiome; Humans; Hyperlipidemias - blood; Hyperlipidemias - drug therapy; Hyperlipidemias - microbiology; Male; Middle Aged; postprandial lipidemia; Postprandial Period - drug effects; probiotics; Probiotics - administration & dosage; Research Paper; Type 2 diabetes; Type 2 diabetes; gut microbiome; dyslipidemia; postprandial lipidemia; berberine; probiotics

Non-fasting lipidemia (nFL), mainly contributed by postprandial lipidemia (PL), has recently been recognized as an important cardiovascular disease (CVD) risk as fasting lipidemia (FL). PL serves as a common feature of dyslipidemia in Type 2 Diabetes (T2D), albeit effective therapies targeting on PL...